Fetal transducers

•

0 likes•17 views

● Functionally equivalent to OEM transducers of manufacturer: Philips, Corometrics, Huntlight/Oxford, Edan, Bionet, Analogic and Spacelabs ● Quality approved with CE certificate ● Transducer types: Ultrasound/Dopper and TOCO ● Included Accessories: -Fetal Direct ECG Cables -Fetal Event Mark - Transducer belts ● 12 months warranty(Except Belts) Our products are not limited only to these listed products. Contact us for more information on our full selection of Medical Cable and Accessories and Medical Repair Parts.More information, please reach out to us at steven.zhou@orantech.com

Recently uploaded

End of Response issues - Code and Rapid Response Workshop

Brian Locke

PSYCHOLOGICAL ASPECTS OF REHAB. IN PHYSIOTHERAPY..pdf

keerti Gour (PT) Shakya

Etiology for RRT and Code Blue Workshop.

Brian Locke

Mike Lowe’s cancer fight lowe strong shirt

rahman018755

Catheterization of the bladder involves introducing a latex or plastic tube through the urethra and into the bladder. The catheter provides a continuous flow of urine in patients unable to control micturition or those with obstructions. It also provides a means of assessing urine output in hemodynamically unstable patients. Because bladder catheterization carries the risk of UTI, blockage, and trauma to the urethra, it is preferable to rely on other measures for either specimen collection or management of incontinence. Types of Catheterization. Intermittent and indwelling retention catheterizations are the two forms of catheter insertion INTERMITTENT CATHETERIZATION introduce a straight single-use catheter long enough to drain the bladder (5 to 10 minutes When the bladder is empty, you immediately withdraw the catheter. COMPLICATION- increases risk of trauma and infection. INDICATION- It is common for people with spinal cord injury or other neurological problems such as multiple sclerosis to perform self– intermittent catheterization up to every 4 hours daily for months or years. UTI rate is lower than for patients with long-term indwelling catheters. INDWELLING CATHETERIZATION- remains in place for a longer period, until a patient is able to void voluntarily or continuous accurate urine measurements are no longer needed The straight single-use catheter has a single lumen with a small opening about 1.3 cm ( 1 2 inch) from the tip. . Urine drains from the tip, through the lumen, and to a receptacle. An indwelling Foley catheter has a small inflatable balloon that encircles the catheter just above the tip. When inflated the balloon rests against the bladder outlet to anchor the catheter in place. The indwelling retention catheter often has two or three lumens within the body of the catheter . One lumen drains urine through the catheter to a collecting tube. A second lumen carries sterile water to and from the balloon when it is inflated or deflated. A third (optional) lumen is sometimes used to instill fluids or medications into the bladder. It is easy to determine the number of lumens by the number of drainage and injection ports at the end of the catheter A second type of intermittent catheter has a curved tip A Coudé catheter is used on male patients who may have enlarged prostates that partly obstruct the urethra. It is less traumatic during insertion because it is stiffer and easier to control than the straight-tip catheter Plastic catheters are suitable only for intermittent use because of their inflexibility Latex catheters are recommended for use up to 3 weeks. Be aware of allergies. Pure silicon or Teflon catheters are best suited for long-term use (2 to 3 months) because of less encrustation at the urethral meatus Balloon sizes range from 3 mL (pediatric) to large postoperative volumes (75 mL). In adults the 5-mL and 30-mL sizes are the most common: The 5-mL size allows for optimal drainage, whereas the 30-mL size is used after pros

Catheterization Procedure by Anushri Srivastav.pptx

AnushriSrivastav

Technology transfer documentation and strategies

Nidhi Joshi

Leadership Style - Code and Rapid Response Workshop

Brian Locke

تقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdf

د حاتم البيطار

Case Presentation: CRYPTOCOCCAL MENINGITIS & ORAL CANDIDIASIS –Opportunistic ...

Dr. Afreen Nasir

Homeopathy Medicine for Diabetes_ Balancing Blood Sugar .pdf

Dharma Homoeopathy

Session-5-Birthing-Practices-Breastfeeding (1).ppt

Medidas Medical Center INC

Delivered on May 15, 2024 by the public and patient engagement team from the George & Fay Yee Centre for Healthcare Innovation, this presentation discusses the nuances of navigating conflict in patient engagement. Learning objectives include: -Understand the importance of using a trauma-informed approach in patient and public engagement -Develop a strategy to work with patient and public partners in addressing conflict as it arises -Employ strengths-based approaches to plan for conflict in your own work

Navigating Conflict in PE Using Strengths-Based Approaches

CHICommunications

Tortora PRINCIPLES OF ANATOMY AND PHYSIOLOGY - Tortora - 14th Ed.pdf

Dr. Afreen Nasir

Case Presentation: Severe microcytic hypochromic iron deficiency anemia with ...

Dr. Afreen Nasir

Session-1-MBFHI-A-part-of-the-Global-Strategy.ppt

Medidas Medical Center INC

Healthcare Finance and M&A, What Comes Next? Presentation by Matthew R. Kittay, National Co-Chair, M&A Practice Group, Fox Rothschild LLP. Includes fundraising and investments. Breakouts by subsector- Healthcare (overall), Healthcare services, Digital health, Biopharma, Pharmatech, Medtech, Healthcare IT. Healthcare transaction distribution breakouts. Exits remain flat. Avoiding common legal pitfalls like IP, compliance, governance structure. Current legislation in health law. IP strategy for healthtech.

mHealth Israel_Healthcare Finance and M&A- What Comes Next

Levi Shapiro

Oppenheimer & Co. Inc, co-Head of Healthcare Investment Banking, Michael Margolis, provides H1 Healthcare Financing, Funding and M&A Overview. Table of Contents 1. Broader Market Overview 2. Biotech M&A Market Overview 3. Private Biotech Financing Market Update 4. Key Advice For Healthcare Companies Current State of Play; Healthcare has Underperformed the Broader Market Over the Last Twelve Months; Signal-to-Noise is Getting Worse; Healthcare IPO Activity has Decreased Significantly Since 20–21 Pandemic Levels; Biotech Financing Activity Has Remained Robust in 2024; Biotech M&A Market Remains Incredibly Active; Biotech M&A Market Remains Incredibly Active; Big Pharma Upcoming Patent Expirations; Since November 2023 Oncology has accounted for over half of all M&A; Oncology, Autoimmune / I&I, and CV & Metabolic Remain the Top Areas in M&A; Small Molecule Beats Out All Other Modalities in M&A Despite IRA Concerns; Value of Big Pharma Acquisitions by Therapeutic Area in Q1 2024; Private Financing Market Update; 2024 Private Placement Activity On Track to Approach, If Not Exceed, 2020 Levels; Oncology, Particularly Solid Tumor, Continues to Attract VC Investors; Despite the IRA, Small Molecules Continue to Attract VC Dollars; Preclinical-Stage Companies Make Up Almost Half of Private Placements in 2023; Valuations by Development Stage – 2023; Typical Biotech Investors Remained Active in Q1 2024; 23 $100M+ Deals were Raised in Q1 2024; Biotech Fundraising Momentum Continued into 2024; Key Advice For Israeli Healthcare Companies; Although Israel has Strong Presence on US Public Markets, There is Room to Grow; Telling Your Story Effectively; Interacting with Investors to Build Long-term Credibility; Seven Simple Rules for Pitch Decks;

Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...

Levi Shapiro

Breaking Down Oppositional Defiant Disorder Treatments

Oppositional Defiant Disorder

The connection between genetics and kidney disease lies in the role of inherited genetic factors that can increase the risk of developing various kidney diseases. Certain kidney diseases, such as Polycystic Kidney Disease (PKD) and Alport Syndrome, have a clear genetic component where mutations in specific genes contribute to the development of these conditions. Understanding these genetic basis is vital for assessing the risk of kidney disease in individuals with family history and for advancing personalized medicine approaches in prevention, diagnosis and treatment. Genetic testing plays a significant role in identifying these predispositions and guiding healthcare strategies.

GENETICS and KIDNEY DISEASES /

AFFIFA HUSSAIN

An overview of Muir Wood Adolescent and Family Services teen treatment programs.

pdamico1

Recently uploaded (20)

End of Response issues - Code and Rapid Response Workshop

PSYCHOLOGICAL ASPECTS OF REHAB. IN PHYSIOTHERAPY..pdf

Etiology for RRT and Code Blue Workshop.

Mike Lowe’s cancer fight lowe strong shirt

Catheterization Procedure by Anushri Srivastav.pptx

Technology transfer documentation and strategies

Leadership Style - Code and Rapid Response Workshop

تقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdf

Case Presentation: CRYPTOCOCCAL MENINGITIS & ORAL CANDIDIASIS –Opportunistic ...

Homeopathy Medicine for Diabetes_ Balancing Blood Sugar .pdf

Session-5-Birthing-Practices-Breastfeeding (1).ppt

Navigating Conflict in PE Using Strengths-Based Approaches

Tortora PRINCIPLES OF ANATOMY AND PHYSIOLOGY - Tortora - 14th Ed.pdf

Case Presentation: Severe microcytic hypochromic iron deficiency anemia with ...

Session-1-MBFHI-A-part-of-the-Global-Strategy.ppt

mHealth Israel_Healthcare Finance and M&A- What Comes Next

Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...

Breaking Down Oppositional Defiant Disorder Treatments

GENETICS and KIDNEY DISEASES /

An overview of Muir Wood Adolescent and Family Services teen treatment programs.

Fetal transducers

Recommended

Recommended

More Related Content

Recently uploaded

Recently uploaded (20)

Featured

Featured (20)